CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

AstraZeneca buys rare disease drugmaker Caelum in $500m deal

By Angela Barnes

12:00, 29 September 2021

AstraZeneca’s logo on its office building in San Francisco
Shares in AstraZeneca rose 3.40% following the announcement – Photo: Shutterstock

AstraZeneca subsidiary Alexion Pharmaceuticals is set to take full control of Caelum Biosciences in a deal worth up to $500m (£371.3m), as the company extends its focus on rare disease drugs.

It means New Jersey-based Caelum will become part of the Alexion division, which AstraZeneca bought for $39bn earlier this year.

Shares in AstraZeneca rose 3.40% on the London Stock Exchange in early trade on Wednesday after it made the announcement on its website.

Rare disease drug development

The latest acquisition gives the pharma giant access to another potentially lucrative rare disease drug, CAEL-101, that is undergoing late-stage trials and has a fast-track status for regulatory review in the US.

It aims to treat AL amyloidosis – a rare, life-threatening disease that damages the heart and kidneys, affecting an estimated 20,000 people across six western countries.

The disease causes abnormal proteins called amyloids to build up in human organs and disrupt their normal function. Caelum’s drug is a type of monoclonal antibody that binds to amyloid deposits to reduce or remove them and improve organ function.

US30

33,201.00 Price
+0.270% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 2

BTC/USD

28,139.30 Price
+5.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

ETH/USD

1,912.60 Price
+4.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.00

US100

14,381.30 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

“With a median survival time of less than 18 months following diagnosis, there is an urgent need for new treatments for this devastating disease,” Alexion chief executive Marc Dunoyer said in a statement.

Financial considerations

In 2019 Caelum and Alexion first entered into a collaboration whereby Alexion acquired a minority stake as well as an exclusive option to acquire the remaining equity in Caelum.

Alexion will pay $150m to buy the remaining stake it does not already own in Caelum and make future payments of up to $350m, depending on milestones achieved, AstraZeneca said.

Since buying Alexion, AstraZeneca has had mixed fortunes with rare disease drugs under development. It reported promising results from trials of a Wilson’s disease drug. However, it abandoned trials for an amyotrophic lateral sclerosis (ALS) drug after it failed to show efficacy.

Read more: Stocks today: Europe, UK rebound from Tuesday’s sell-off

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading